Literature DB >> 24832015

Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.

Norio Sugaya1, Yuko Sakai-Tagawa, Masahiro Bamba, Rieko Yasuhara, Masahiko Yamazaki, Chiharu Kawakami, Yoshio Yamaguchi, Yoshiaki Ide, Masataka Ichikawa, Keiko Mitamura, Yoshihiro Kawaoka.   

Abstract

BACKGROUND: Shedding of the pandemic virus during an influenza pandemic is thought to persist longer than shedding of influenza viruses during annual influenza seasons, because people have much less immunity against a pandemic influenza. A correlation is thought to exist between the length of virus shedding and the clinical severity of influenza illness.
METHODS: We compared the virus isolation rates of children with pandemic A H1N1/09 influenza infection and children with A H3N2 influenza infection after the patients had been treated with one of three neuraminidase inhibitors (NAI) such as peramivir, laninamivir and oseltamivir. The clinical effectiveness of each NAI was assessed on the basis of the duration of the febrile period after the start of treatment.
RESULTS: Influenza viruses were isolated from 15 of the 34 patients in the A H3N2 group (mean age 6.2 years) and from 4 of the 25 patients in the A H1N1/09 (mean age 5.6 years) virus group (44.1% versus 16.0%; P<0.05). However, the differences between the duration of fever in the patients in the A H3N2 group and A H1N1/09 group after treatment with the NAIs were not significant.
CONCLUSIONS: The virus isolation rates after treatment with each of the NAIs were significantly lower in the A H1N1/09 group, suggesting that the pandemic A H1N1/09 virus was more sensitive to the NAIs than the seasonal A H3N2 virus was. Clinically, there were no significant differences in the effectiveness of the NAIs between the H1N1/09 infected group and H3N2 infected group.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24832015     DOI: 10.3851/IMP2798

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  8 in total

1.  Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice.

Authors:  Charlene Ranadheera; Mable W Hagan; Anders Leung; Brad Collignon; Todd Cutts; Steven Theriault; Carissa Embury-Hyatt; Darwyn Kobasa
Journal:  J Virol       Date:  2016-10-14       Impact factor: 5.103

Review 2.  Japanese Surveillance Systems and Treatment for Influenza.

Authors:  Hassan Zaraket; Reiko Saito
Journal:  Curr Treat Options Infect Dis       Date:  2016-10-10

3.  The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patients.

Authors:  John Palmer; Hana M Dobrovolny; Catherine A A Beauchemin
Journal:  Sci Rep       Date:  2017-01-09       Impact factor: 4.379

4.  Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan.

Authors:  Norio Sugaya; Masayoshi Shinjoh; Chiharu Kawakami; Yoshio Yamaguchi; Makoto Yoshida; Hiroaki Baba; Mayumi Ishikawa; Mio Kono; Shinichiro Sekiguchi; Takahisa Kimiya; Keiko Mitamura; Motoko Fujino; Osamu Komiyama; Naoko Yoshida; Kenichiro Tsunematsu; Atsushi Narabayashi; Yuji Nakata; Akihiro Sato; Nobuhiko Taguchi; Hisayo Fujita; Machiko Toki; Michiko Myokai; Ichiro Ookawara; Takao Takahashi
Journal:  Euro Surveill       Date:  2016-10-20

5.  The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study.

Authors:  Nobuo Hirotsu; Yutaka Saisho; Takahiro Hasegawa
Journal:  Influenza Other Respir Viruses       Date:  2018-12-28       Impact factor: 4.380

6.  A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment.

Authors:  Jui-Yi Chen; Shih-Kai Wei; Chih-Cheng Lai; Teng-Song Weng; Hsin-Hua Wang
Journal:  Medicina (Kaunas)       Date:  2020-02-05       Impact factor: 2.430

7.  Effectiveness of four types of neuraminidase inhibitors approved in Japan for the treatment of influenza.

Authors:  Momoko Mawatari; Reiko Saito; Akinobu Hibino; Hiroki Kondo; Ren Yagami; Takashi Odagiri; Ikumi Tanabe; Yugo Shobugawa
Journal:  PLoS One       Date:  2019-11-07       Impact factor: 3.240

8.  Efficacy and Safety of Intravenous Peramivir Compared With Oseltamivir in High-Risk Patients Infected With Influenza A and B Viruses: A Multicenter Randomized Controlled Study.

Authors:  Shigeki Nakamura; Taiga Miyazaki; Koichi Izumikawa; Hiroshi Kakeya; Yutaka Saisho; Katsunori Yanagihara; Yoshitsugu Miyazaki; Hiroshi Mukae; Shigeru Kohno
Journal:  Open Forum Infect Dis       Date:  2017-06-19       Impact factor: 3.835

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.